Quality matters: Challenges in 2023 across the life sciences supply chain

11

The Life Sciences industry has never needed a robust manufacturing and supply chain Quality backbone more than it does now. As a result of the pandemic, then further aggravated by the war situation in Europe, the problem of shortages of some medicines persisted in 2022. The continued/repeat closure of China and the difficulties in the supply of raw materials presented a major problem, forcing pharma companies to rethink their reliance on far-flung markets for APIs and other raw materials. To ensure supply security, manufacturers have had to review their sourcing options and, in many cases, opt for alternatives closer to home – despite the associated expense. This activity continues, and with it the need to review the quality performance and compliance records of new suppliers or alternative manufacturing sites in Europe or North America.